论文部分内容阅读
目的:探讨ALT升高的ACS患者应用他汀类药物的可行性。方法:ACS患者120例,根据入院时血清ALT值分为ALT升高组38例,ALT正常组82例。两组患者在入院接受常规治疗的同时,给予普伐他汀20mg/d,分别于治疗第10日、30日复查ALT,比较两组治疗前后ALT的变化,计算两组治疗后ALT升高的发生率。结果:普伐他汀治疗第10日及第30日,ALT升高组与ALT正常组ALT升高的发生率比较,均无明显差异(5%比2%,3%比2%,均为P>0.05)。结论:ALT升高的ACS患者应用他汀类药物30日内不会出现肝毒性。
Objective: To investigate the feasibility of using statins in ACS patients with elevated ALT. Methods: One hundred and twenty patients with ACS were divided into three groups according to their serum ALT levels: ALT elevated group (38 cases) and ALT normal group (82 cases). At the same time of receiving pravastatin 20mg / d, the two groups were given pravastatin 20mg / d, ALT was reexamined on the 10th and 30th day of treatment respectively, and the change of ALT before and after treatment was compared between two groups to calculate the increase of ALT rate. Results: There was no significant difference in the incidence of ALT between pravastatin treatment group on the 10th and the 30th day in ALT elevated group and normal ALT group (5% vs 2%, 3% vs 2%, P > 0.05). CONCLUSIONS: Hepatotoxicity does not occur within 30 days of statin use in ACS patients with elevated ALT.